Department of Medicine, Division of Cardiology, Columbia University Medical Center, New York, NY 10032, USA.
Circ Heart Fail. 2013 May;6(3):527-34. doi: 10.1161/CIRCHEARTFAILURE.112.000092. Epub 2013 Mar 15.
Alternate waiting list strategies expand listing criteria for patients awaiting heart transplantation (HTx). We retrospectively analyzed clinical events and outcome of patients listed as high-risk recipients for HTx.
We analyzed 822 adult patients who underwent HTx of whom 111 patients met high-risk criteria. Clinical data were collected from medical records and outcome factors calculated for 61 characteristics. Significant factors were summarized in a prognostic score. Age >65 years (67%) and amyloidosis (19%) were the most common reasons for alternate listing. High-risk recipients were older (63.2±10.2 versus 51.4±11.8 years; P<0.001), had more renal dysfunction, prior cancer, and smoking. Survival analysis revealed lower post-HTx survival in high-risk recipients (82.2% versus 87.4% at 1-year; 59.8% versus 76.3% at 5-year post-HTx; P=0.0005). Prior cerebral vascular accident, albumin <3.5 mg/dL, re-HTx, renal dysfunction (glomerular filtration rate <40 mL/min), and >2 prior sternotomies were associated with poor survival after HTx. A prognostic risk score (CARRS [CVA, albumin, re-HTx, renal dysfunction, and sternotomies]) derived from these factors stratified survival post-HTx in high-risk (3+ points) versus low-risk (0-2 points) patients (87.9% versus 52.9% at 1-year; 65.9% versus 28.4% at 5-year post-HTx; P<0.001). Low-risk alternate patients had survival comparable with regular patients (87.9% versus 87.0% at 1-year and 65.9% versus 74.5% at 5-year post-HTx; P=0.46).
High-risk patients had reduced survival compared with regular patients post-HTx. Among patients previously accepted for alternate donor listing, application of the CARRS score identifies patients with unacceptably high mortality after HTx and those with a survival similar to regularly listed patients.
交替候补名单策略扩大了等待心脏移植(HTx)的患者的名单标准。我们回顾性分析了被列为 HTx 高危受体的患者的临床事件和结局。
我们分析了 822 名接受 HTx 的成年患者,其中 111 名患者符合高危标准。从病历中收集临床数据,并为 61 个特征计算预后因素。显著因素总结在预后评分中。年龄>65 岁(67%)和淀粉样变性(19%)是交替列入名单的最常见原因。高危受体年龄较大(63.2±10.2 岁与 51.4±11.8 岁;P<0.001),肾功能不全、既往癌症和吸烟更为常见。生存分析显示高危受体 HTx 后生存率较低(1 年时为 82.2%,5 年时为 59.8%;P=0.0005)。既往脑卒、白蛋白<3.5mg/dL、再次 HTx、肾功能不全(肾小球滤过率<40ml/min)和>2 次开胸术与 HTx 后生存不良相关。从这些因素中得出的预后风险评分(CARRS[卒、白蛋白、再次 HTx、肾功能不全和开胸术])将高危(3 分以上)和低危(0-2 分)患者的 HTx 后生存分层(1 年时为 87.9%和 52.9%;5 年时为 65.9%和 28.4%;P<0.001)。低危候补患者的生存率与常规患者相当(1 年时为 87.9%和 87.0%,5 年时为 65.9%和 74.5%;P=0.46)。
高危患者 HTx 后生存率较常规患者低。在之前被接受为候补供体的患者中,应用 CARRS 评分可以识别出 HTx 后死亡率过高的患者,以及生存率与常规列入名单的患者相似的患者。